Insulet Lowers Sales Forecast Amid Sluggish U.S. Insulin Pump Growth

Insulet Corporation, a leader in medical devices, has adjusted its annual sales growth forecast following a slowdown in U.S. sales of its Omnipod insulin pumps. The announcement led to a nearly 21% drop in the company's shares. Chief Executive Officer Ashley McEvoy highlighted the challenges faced in retaining customers and lower-than-expected usage among type 2 diabetes patients during the first 90 days of using the Omnipod system.

Revised Revenue Projections

The company now anticipates its 2026 revenue to grow between 20% and 22%, a slight decrease from the prior forecast of 21% to 23%. This revision comes amid softer sales projections for the second half of the year in the U.S. market. Chief Financial Officer Flavia Pease noted that the updated guidance accounts for ongoing trends of weak retention and usage.

Specifically, Insulet has reduced its forecast for U.S. Omnipod sales growth to a range of 17% to 19%, down from the previous 20% to 22%. Conversely, the company has raised its international sales growth expectations to between 30% and 32%, up from 26% to 28%.

Focus on Type 2 Diabetes Market

McEvoy acknowledged that the challenges were not linked to competitive pressures, pricing issues, or the impact of GLP-1 medications. Instead, she pointed to execution issues in supporting type 2 diabetes patients during their initial use of the Omnipod device. She stated, "We should have understood some of these type 2 trends sooner and done a better job of adapting our commercial and customer service model to the needs of this really important customer base."

Despite these challenges, Insulet reported a 24.6% increase in quarterly Omnipod sales, reaching $795.9 million. U.S. sales rose by 20.1% to $544.1 million. The company also posted a second-quarter adjusted profit of $1.66 per share, surpassing analysts' expectations of $1.45 per share, according to data from LSEG.

Investor Concerns

Analysts have expressed concerns about the potential for further declines in U.S. growth. J.P. Morgan analyst Robbie Marcus noted that with the deceleration in trends during the second half of the year, there is a fear that U.S. growth could fall to near 10% or even lower in 2027. This sentiment has contributed to the negative reaction in the stock market following the revised guidance.